Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
YN001-004 in Patients With Coronary Atherosclerosis in Australia
NCT06700720 · Beijing Inno Medicine Co., Ltd. · PHASE2 · terminated · last registry update 2026-09-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated at the request of the Sponsor.” | – | Registry record, Beijing Inno Medicine Co., Ltd. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PCSK9 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-04Results posted on the registry: Duke University, Alirocumab and Cemiplimab (NCT05553834)
- 2026-09-28Results posted on the registry: LIB Therapeutics LLC, lerodalcibep (NCT04797104)
- 2026-08-20Phase 3 first posted: LIB Therapeutics LLC, Lerodalcibep (NCT07775339)
- 2026-08-18Results posted on the registry: Stanford University, alirocumab + placebo (NCT03537742)
- 2026-07-07Phase 3 first posted: Guangdong Provincial People's Hospital, CAPOX (oxaliplatin/capecitabine) + Sintilimab (NCT07686796)
- 2026-06-25Results posted on the registry: Amgen, Evolocumab + Placebo (NCT03872401)
- 2026-05-22Also stopped (terminated): Henan Institute of Cardiovascular Epidemiology, Rosuvastatin 20 mg + Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA] (NCT05613426)
- 2026-05-14Phase 3 first posted: Middle East North Africa Stroke and Interventional Neurotherapies Organization, Alirocumab + Placebo (NCT07586540)
- 2026-05-12Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Cobimetinib (NCT03337698)
- 2026-05-12Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Cobimetinib (NCT03337698)
- 2026-05-05Results posted on the registry: Eziafa Oduah, MD, PhD, MPH, Nivolumab + Ipilimumab (NCT05144529)
- 2026-05-05Also stopped (terminated): Eziafa Oduah, MD, PhD, MPH, Nivolumab + Ipilimumab (NCT05144529)
- 2026-04-16Results posted on the registry: Brigham and Women's Hospital, Evolocumab (NCT04608474)
- 2026-04-14Results posted on the registry: Novartis Pharmaceuticals, Inclisiran Sodium + Placebo (NCT05192941)
- 2025-12-01Phase 3 first posted: Beijing Anzhen Hospital, Treatment with PCSK9 inhibitors (NCT07256197)
- 2025-11-24Results posted on the registry: Johns Hopkins University, Evolocumab + Placebo (NCT03515304)
- 2025-11-21Phase 3 first posted: Beijing Tiantan Hospital, High target group + Low target group (NCT07242599)
- 2025-10-23Results posted on the registry: Johns Hopkins University, Evolocumab + Placebos (NCT04082442)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision